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Abstract: Overactive bladder syndrome is one of the lower urinary tract dysfunctions 
with the highest number of scientific publications over the past two decades. This sho-
ws the growing interest in better understanding this syndrome, which gathers symp-
toms of urinary urgency and increased daytime and nighttime voiding frequency, with 
or without urinary incontinence and results in a negative impact on the quality of life 
of approximately one out of six individuals – including both genders and almost all 
age groups. The possibility of establishing the diagnosis just from clinical data made 
patients’ access to specialized care easier. Physiotherapy resources have been incor-
porated into the urological daily practice. A number of more selective antimuscarinic 
drugs with consequent lower adverse event rates were released. Recently, a new class of 
oral drugs, beta-adrenergic agonists has become part of the armamentarium for Ove-
ractive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation 
are routine modalities of treatment for refractory cases. During the 1st Latin-American 
Consultation on Overactive Bladder, a comprehensive review of the literature related to 
the evolution of the concept, epidemiology, diagnosis, and management was conduc-
ted. This text corresponds to the first part of the review Overactive Bladder 18-years.
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InTRODuCTIOn
Overactive bladder syndrome refers to a 
set of lower urinary tract symptoms that leads to 
a great negative impact on the quality of life of 
a significant part of the population. In the last 18 
years – since the term “overactive bladder syndro-
me” was first introduced to the urology community, 
approximately five thousand articles have been pu-
blished in specialty journals. During this period, we 
have witnessed surprising facts, such as the high 
percentage of people affected by overactive blad-
der symptoms, against the small number of the-
se affected people seeking medical attention or on 
adequate treatment. By putting the symptoms of 
urgency, increased daytime and nighttime voiding 
frequency and occasional urinary incontinence all 
together under the same definition, a simplification 
in establishing the diagnosis and selecting an ade-
quate treatment occurred. Within these almost two 
decades, a number of drugs have been – and con-
tinue to be – added to the arsenal of therapeutic 
options. Minimally invasive approaches such as the 
intravesical injection of botulinum toxin and sacral 
neuromodulation beat off and placed more com-
plex surgical interventions, such as bladder aug-
mentation, as a condition of exception. 
Several urological societies proposed gui-
delines for overactive bladder with the purpose 
of standardizing its diagnosis and treatment. Al-
though evidence-based medicine provides us with 
a solid foundation to support the approaches to be 
adopted, we often see some detachment from what 
we experience in the daily practice. A variety of 
systematic reviews have been published on overac-
tive bladder, most of them being focused on specific 
topics, such as the use of certain drugs, the impact 
on the quality of life, or even the role of the overac-
tive bladder in selected populations, among which 
are the elderly and women, or associated with other 
urinary disorders such as painful bladder syndrome 
or mixed urinary incontinence. 
With the purpose of integrating opinions 
and experiences of Latin-American urologists, 
the 1st Latin-American Consultation on Overactive 
Bladder was established. Twenty-seven urologists 
treating urinary dysfunctions in Argentina, Bra-
zil, Chile, Colombia, Mexico, and Venezuela par-
ticipated in this event. Five groups were formed, 
and a topic was assigned to each one to develop: 
The Concept and Diagnosis of Overactive Bladder; 
Epidemiology; Conservative Non-Pharmacological 
Management; Pharmacological Management; and 
Refractory Overactive Bladder. 
A systematic search for publications in 
the period from 1997 to 2014 was performed in 
“PubMed” and “Bireme,” which give access to “LI-
LACS,” “IBECS,” “MEDLINE,” “Cochrane Library,” 
and “SciELO” databases, with the main search term 
being overactive bladder. The searches, carried out 
by two independent investigators, targeted each 
group’s assigned topic, as provided in Table 1. 
Initially, 2,508 papers were identified. In-
complete texts, abstracts, and articles on repeated 
or doubled topics were excluded. The search was 
limited to articles published in English, Portuguese, 
and Spanish. The articles forming the database for 
the present review were selected according to their 
scientific level of evidence and their relevance for 
the clinical practice. In the end, 236 articles were 
selected and forwarded to the members of each 
group in accordance with the assigned topic. Each 
group reviewed the selected articles and prepared 
a summary. The huge number of articles available 
in the literature made it impossible to include se-
veral publications, many of which with unarguable 
scientific and clinical relevance. When the same to-
pic was addressed in two or more articles, the most 
recent and complete one was selected. 
Each group’s summaries were presented in a 
joint session, and after being discussed and appro-
ved, they underwent a compilation and adjustment 
process that resulted in the present text. The pri-
mary objective of this review article is to provide a 
practical approach about the Overactive Bladder in 
its different aspects, from concept to treatment of 
refractory cases according to the interpretation of 
Latin-American urologists that have great expertise 
in urinary dysfunctions. The first part will address 
the overactive bladder concept and classification, 
epidemiology, diagnosis, and conservative non-
-pharmacological management.
Concept and classification of overactive bladder 
The term Overactive Bladder was first intro-
duced to the scientific community in 1997 during 
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the Consensus Conference named “The Overactive 
Bladder: From Basic Science to Clinical Manage-
ment” (1). Since then, the definition of overactive 
bladder had been reviewed several times and was fi-
nally standardized by IUGA (International Urogyne-
cological Association) and ICS (International Conti-
nence Society) in 2010 as “urinary urgency, usually 
with frequency and nocturia, with or without ur-
gency urinary incontinence, in the absence of any 
urinary tract infection or another obvious patholo-
gy” (2). In those terms, therefore, it is a definition 
based on symptoms only. Although the symptoms 
are suggestive of detrusor overactivity, this is not a 
rule of thumb, being more commonly seen in ove-
ractive bladder patients with urinary incontinence – 
also called wet overactive bladder (3). Thus, the ter-
ms overactive bladder and detrusor overactivity are 
distinct, with the latter being a finding in an uro-
dynamic exam. The globally accepted simple and 
pragmatic definition of overactive bladder meets the 
purpose of describing a common condition, which 
allows establishing an initial treatment without 
having to go through expensive, complex exams. 
However, there are controversial aspects that could 
cause confusion, either in the diagnosis or the im-
possibility of determining how severe the problem is 
or even in evaluating the treatment results. 
The current definition of overactive bladder 
allows the inclusion of neurological conditions im-
pacting the bladder-sphincter functioning referred 
as Neurogenic Overactive Bladder as well as non-
-neurogenic conditions – the Idiopathic Overactive 
Bladder. However, in practice, the term Overactive 
Bladder was generally established for non-neuro-
genic situations. In the present work, we will keep 
the approach restrict to the Idiopathic overactive 
bladder, simply referred to as Overactive bladder.
Epidemiology of overactive bladder 
The prevalence of lower urinary tract symp-
toms has been studied in several countries, with a 
methodology that is not always even. Differences 
in the study population, age, gender, ethnicity, and 
geographic location, as well as in the inclusion and 
exclusion criteria impact the results reported by the 
different studies. 
One of the first publications (Milsom et 
al., 2001) reported a 16.6% prevalence in 16,776 
individuals aged 40 years or older, in European 
countries (4), while the EPIC (European Prospecti-
ve Investigation into Cancer and Nutrition) study 
evaluated 19,165 individuals, also in four European 
countries and Canada, and found a prevalence of 
11.8% – with the older the patient, the higher the 
rates in both genders (5). 
A regional study conducted in Austria of an 
urban population of 2,418, 20-91 year-old men and 
women showed a 13.5% prevalence, with substan-
tial increase after 40 years of age. Among the Eu-
ropean countries, the lowest prevalence was seen in 
Finland. In a cohort of 3,727 18-79 year-old indivi-
duals, the prevalence in that country was only 8%. 
The authors suggested that the use of inaccurate 
criteria and population selection may have overes-
timated the prevalence of overactive bladder repor-
ted in other publications (6). In the United States, 
the NOBLE (National Overactive Bladder Evalua-
tion) study showed a 16.5% prevalence of overacti-
ve bladder in a sample of 5,204 adults aged over 18 
years (7). In 2010, a multicentric assessment using 
the OAB-V8 questionnaire was conducted in Ve-
nezuela in a total of 3,407 18-75 year-old adults, 
with 38% of them being males. The prevalence of 
overactive bladder in this population was 21% (8). 
Other studies conducted in Latin America found a 
similar prevalence; 23.4% and 18.9%, in Argentina 
and Brazil, respectively (9, 10). 
Men and women are equally affected. The 
prevalence of overactive bladder reported by the 
NOBLE study was 16.9% in women and 16.0% in 
men (7). In the EPIC study, 13% of women and 11% 
of men had overactive bladder (5). In Finland, its 
prevalence in women was 9.3% and 6.5% in men 
(6). In Venezuela, the study revealed that women 
were more often affected than men – 25.6% and 
13.7%, respectively (8). The same result was obser-
ved by Teloken et al., in Brazil, where the condition 
was reported by 23.3% of women and 14% of men 
(10), as well as Temml et al., with 16.8% of women 
and 10.2% of men reporting it (11). 
Among the overactive bladder patients, the 
main reasons to search for medical attention inclu-
ded increased voiding frequency, urinary urgency, 
and urgency urinary incontinence (12). According 
to Milsom et al., among the 17% of overactive bla-
dder patients identified in their study, 14% reported 
ibju | Overactive bladder
191
Table 1 - Method of search of scientific publication at pubMed, Bireme
Groupst Strategy of search Filters Total of 
identified 
articles
Total of 
selected 
articles
Concept and diagnosis of 
Overactive bladder
( "Urinary Bladder, Overactive/
classification"[Mesh] OR 
"Urinary Bladder, Overactive/
diagnosis"[Mesh] OR "Urinary 
Bladder, Overactive/etiology"[Mesh] 
OR "Urinary Bladder, Overactive/
pathology"[Mesh] OR 
"Urinary Bladder, Overactive/
physiopathology"[Mesh] ) OR 
( "Urinary Incontinence, Urge/
classification"[Mesh] OR  
"Urinary Incontinence, Urge/
diagnosis"[Mesh] OR  "Urinary 
Incontinence, Urge/etiology"[Mesh] 
OR  "Urinary Incontinence, 
Urge/pathology"[Mesh] OR  
"Urinary Incontinence, Urge/
physiopathology"[Mesh] )
English/spanish/portuguese 
+ abstract available + 
01/01/1985 a 31/05/2014 + 
humans + >19 years
799 53
Epidemiology (Urinary Incontinence, Urge or 
Urinary Bladder, Overactive) and 
(economics or epidemiology)
English/spanish/portuguese 
+ abstract available + 
01/01/1985 a 31/05/2014 + 
humans + >19 anos
713 51
Conservative
Non-Pharmacological 
Management
(Urinary Incontinence, Urge or 
Urinary Bladder, Overactive) and 
(diet therapy or drug therapy 
or prevention or control or 
rehabilitation or surgery or treatment 
or therapy)
English/spanish/portuguese 
+ abstract available + 
01/01/1985 a 31/05/2014 + 
humans + >19 anos
Clinical trials, Review, 
Randomized Clinical Trial
996
35
Pharmacological Management 71
Refractory
Overactive Bladder
26
increased voiding frequency; 9% reported urgency 
symptoms; and 6% reported urge-incontinence. 
About 80% had had the symptoms for at least one 
year and 49% for at least 3 years (4). Similar data 
were observed in a multicentric study conducted 
in Spain involving 1,754 40-92 year-old patients 
who came to a urological appointment due to their 
overactive bladder symptoms. The most common-
ly seen symptoms were urgency (95.2%), nocturia 
(94.5%), and urinary frequency higher than 8 voids 
a day (84.2%). In this study, 61% of patients were 
“unsatisfied” or “very unsatisfied” with their cur-
rent urinary condition (13). 
The impact of untreated overactive bladder 
is high in the adult population, notably affecting 
social and professional relationships. All aspects of 
the quality of life may be impacted, including the 
psychological, social, household, and sexual func-
tion domains. The condition may also reduce one’s 
productivity at work, and in another domain, lead 
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to a repulse behavior towards the sexual activity 
(7, 14). A British study including men and women 
showed that 36% believed this disorder “greatly” 
or “significantly” affected their lives. As a result, 
major behavioral changes were made by a signifi-
cant portion of the patients, such as liquid intake 
reduction by 35%, bathroom mapping by 33%, and 
going out of home less frequently by 15% (15). 
Nocturia featuring two or more times per night 
affects one third of men and women with overac-
tive bladder (5). In the NOBLE study, the quality of 
life and quality of sleep were significantly impai-
red among overactive bladder patients (7). A higher 
risk of falls and fractures among the elderly with 
urgency urinary incontinence is associated with the 
rush to reach a bathroom in order to avoid leakages. 
This age group’s higher susceptibility results from 
the aggravation of the urinary incontinence with 
ageing together with the diminishing of mobility. 
Older patients with urgency urinary incontinence 
are twice as likely to have falls and fractures, when 
compared with incontinence-free patients (14). 
Overactive bladder syndrome negatively 
impacts the public health system and economic re-
sources as well, when we consider the highest in-
cidence in the older population. It should also be 
highlighted that the 65+ year-old population will 
double in the next few decades. The estimated an-
nual cost of overactive bladder in the North-Ame-
rican adult community is as much as 24.9 billion 
dollars. If we consider those patients occasionally 
experiencing symptoms too, then the medical and 
non-medical expenses and indirect costs soar to 
36.5 billion dollars (16).
Diagnosis 
The initial evaluation, as it is usual in the 
medical practice, should include anamnesis and 
physical exam. During this step, it is critical to de-
termine the onset time of symptoms; their abrupt 
nature or not; presence of aggravating factors; 
successful previous treatments; remission periods; 
need for protection measures against urinary le-
akages, such as diapers; and the consequent im-
pact of symptoms on the quality of life. Physical 
exam allows identifying pelvic masses, vesical or 
intestinal distension, genital prolapse, and increa-
sed prostatic volume, which are useful for the diffe-
rential diagnosis from other pathologies showing 
a symptomatology similar to overactive bladder. 
Although we did not include neurogenic conditions 
in the present review, it is important to perform a 
brief neurological exam in the context of this eva-
luation. 
Voiding diary is one of the most important 
tools to assess the lower urinary tract symptoms, as 
it provides quantifiable, objective data that are also 
useful to analyze the evolution after the prescrip-
tion of treatment (17, 18). The voiding frequency 
and the volume at each void are the main elements 
of the diary, which allow distinguishing asympto-
matic patients and overactive bladder individuals 
(19-21). In order to verify the trustfulness of the 
symptoms reported in three-day versus seven-day 
diaries, Dmochowski et al. studied 881 patients with 
overactive bladder. Both periods of data collection 
showed equivalent accuracy and reproducibility, 
with the three-day diary being considered more 
convenient by patients (20). Therefore, a three-
-day voiding diary containing the time and volume 
of each void and avoiding the inclusion of other 
information (such as liquid intake) that adds few 
relevant data and makes patient adherence more 
difficult is enough to assess the lower urinary tract 
symptoms in the clinical practice (18). 
Questionnaires that evaluate overactive bla-
dder patients are critical measuring tools when con-
ducting scientific studies. They may be didactically 
classified as specific questionnaires, urinary inconti-
nence questionnaires, quality-of-life questionnaires, 
and questionnaires of the impact of urinary inconti-
nence on the quality of life. Among the several ques-
tionnaires available worldwide, the following show 
the highest applicability: ICIQ-OAB, OAB-SF, OAB 
V-8, ICIQ-OABqol (22-25). However, these question-
naires should not be regarded as definitive diagnostic 
tools. They are designed to standardize and enable 
data comparison in clinical trials and more objective-
ly measure the impact of the symptoms on patients’ 
quality of life (26-29). It should also be stressed that 
questionnaires need to be validated in the country 
language before being applied.
Complementary tests 
Due to its low cost and non-invasive nature, 
urinalysis is requested for virtually all patients with 
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overactive bladder symptoms (30, 31). For most pa-
tients, once urinary infection and hematuria are ru-
led out, treatment may be initiated. The presence of 
microscopic hematuria may suggest the existence 
of a urinary tract neoplasm or other pathologies, 
and it deserves additional investigation. 
The ultrasound of the urinary tract is not 
recommended for initial evaluation of overactive 
bladder patients; however, it may be useful for a di-
fferential diagnosis. In addition, it allows measuring 
the post-voiding residual volume in a non-invasive 
fashion, and through this, indicating the existence 
of infravesical obstruction or detrusor failure. 
While the diagnosis of overactive bladder 
is essentially clinical, there is a lot of discussion 
on the use of urodynamic exam in evaluating the 
diagnosis of the syndrome. Despite being consi-
dered the gold standard for evaluation of low uri-
nary tract symptoms, its invasive nature and the 
fact that it places a risk of urinary infection usually 
make the urodynamic exam indicated for refractory 
patients to the conservative treatments of overacti-
ve bladder (32). Another limiting factor to its rou-
tine use is the low correlation of urinary symptoms 
with urodynamic findings in many cases. This was 
well demonstrated in a review by Digesu, in which 
the urodynamic results and the clinical diagnosis of 
overactive bladder matched in 21% of patients only 
(33). Few guidelines, like the one from France, re-
commend urodynamic testing for initial evaluation 
of patients with low urinary tract symptoms (34). 
On the other hand, the Italian and UK guidelines 
only recommend the urodynamic investigation in 
patients at risk of renal complications (35, 36). The 
urodynamic testing should be performed following 
good medical practice criteria when symptoms do 
not allow for a clear diagnosis, when empirical tre-
atment fails, or in cases where more invasive treat-
ments are considered (37, 38). 
There is consensus on the fact that perfor-
ming cystoscopy is not useful to diagnose ove-
ractive bladder. Its indication is limited to ca-
ses where there is a suspicion of bladder cancer. 
For example, in the study by Ryan, only 4.1% 
(14/340) of bladder cancer patients experienced 
exclusively overactive bladder-related symp-
toms, with carcinoma in situ being the one with 
the highest positive correlation (21%) (39).
New perspectives for the diagnosis of overactive 
bladder 
The identification of lower urinary tract 
functional disorder biomarkers, such as for overac-
tive bladder, faces several limitations (17). To date, 
no biomarkers have demonstrated to be effective as 
a tool for use in the daily practice. Yet, some bio-
markers have been considered useful as potential 
tools for diagnosis and therapeutic monitoring. 
Overactive bladder biomarkers may contri-
bute to the understanding of the urinary storage 
symptoms. They are involved in the possible ove-
ractive bladder-associated changes that occur in 
the bladder or nervous system and that may be 
assessed through the dosing of plasma or urine 
molecules: neurotrophins, adenosine triphospha-
te (ATP), prostaglandins, C-reactive protein (RCP), 
and cytokines. Other biomarkers may be assessed 
through the measurement of bladder wall-related 
events, such as wall thickness and oxyhemoglobin 
and deoxyhemoglobin concentration (40). 
The neuronal growth factor (NGF) modula-
tes the release of neurotransmitters and reduces the 
sensitivity threshold of nociceptive fibers; therefo-
re, its neutralization diminishes the hyperreflexia 
in an animal model of spine injury (41). The NGF 
is produced in the urothelium and vesical smooth 
musculature. Clinical and experimental data have 
shown a direct association between the increased 
NGF expression in the vesical tissue and in the uri-
ne (42-44). However, an issue in the use of NGF as 
an overactive bladder biomarker is the fact that it 
can be elevated in other clinical conditions as well, 
such as painful bladder syndrome, urinary infec-
tions, urinary lithiasis, and bladder tumors (45, 46). 
Qu et al. conducted a meta-analysis that identified 
only eight controlled studies (47). In all of them, 
patients with overactive bladder symptoms showed 
higher urinary NGF levels than healthy individuals 
and achieved lower NGF levels after having been 
effectively treated. In the subgroup analysis, the 
NGF was demonstrated to be higher in wet ove-
ractive bladder than dry overactive bladder pa-
tients. However, no differences were found when 
the NGF levels of overactive bladder patients and 
painful bladder syndrome patients were compared. 
The authors concluded that the urinary NGF could 
be a useful biomarker to diagnose overactive blad-
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der and a potential biomarker to differentiate cases 
with and without associated urinary incontinence, 
but it could not be used to differentiate overactive 
bladder from painful bladder syndrome (46). 
Urinary prostaglandins and cytokines were 
also proposed as overactive bladder markers. Pros-
taglandin E2 (PGE2) was more widely studied and 
has been considered as superior to NGF as a discri-
minatory marker. According to the study by Kim 
et al., the PGE2 levels were lower in a subgroup of 
overactive bladder and detrusor hypocontractility 
patients – as demonstrated in the urodynamic tes-
ting – than in overactive bladder patients without 
detrusor hypocontractility (44). Other cytokines 
were also high in the urine of overactive bladder 
patients, including monocyte chemotactic pro-
tein-1 (MCP-1) and the soluble fraction of the CD40 
ligand (scd40L) (48, 49). However, their exclusive 
association with overactive bladder symptoms is 
not well established. This was also seen with the 
dosing of other biomarkers such as RCP and ATP 
with low sensitivity and specificity (50-55).
Non-pharmacological and non-surgical manage-
ment of overactive bladder 
It is important that patients understand that 
overactive bladder is not a disease; rather, it is a 
syndromic complex and it is not life-threatening. 
After evaluation and rule-out of other conditions 
that could require further investigation, patients 
should be educated about the therapeutic options, 
including the non-treatment. 
Non-pharmacological conservative treat-
ment of overactive bladder may involve a number 
of measures targeting to increase the voiding inter-
val, improve bladder capacity, reduce urinary ur-
gency and nocturia episodes, and prevent involun-
tary loss of urine. Interventions in lifestyle-related 
factors, collectively referred to as behavioral the-
rapy, were associated with potential improvement 
of symptoms. However, there are few studies with 
high level of scientific evidence evaluating specific 
chances in the lifestyle as the single treatment. 
The majority of the studies evaluating the 
influence of caffeinated beverage consumption in-
dicate that this may worsen the overactive bladder 
symptoms and urinary incontinence, due to either 
their diuretic proprieties or their potential bladder 
irritation effect (56-59). Bryant et al., in a rando-
mized clinical trial, compared women with a daily 
consumption of 965 mg of caffeine and a control 
group with an average consumption of 279 mg 
(60). In the control group, lower urgency (61% vs. 
12%) and fewer episodes of incontinence (55% vs. 
26%) was observed, although the values did not 
reach statistical significance. In another randomi-
zed, crossover, double-blind study, though, the re-
placement of caffeine by decaffeinated beverages 
did not show to improve the patients’ urgency and 
frequency symptoms (61). 
Swithinbank et al. evaluated the effect of 
liquid intake reduction in 30 women with idiopa-
thic detrusor overactivity and observed a signifi-
cant reduction of voiding frequency, urgency and 
incontinence symptoms as well as improvement 
of the quality of life (62). In a controlled study of 
overactive bladder patients, a significant reduction 
of frequency, urgency and nocturia was observed 
when patients reduced the liquid intake by 25% or 
more (63). However, restricting the consumption of 
liquids may have adverse effects, including urinary 
infection predisposition, dehydration, calculus for-
mation, and constipation, which contribute to the 
development of an overactive bladder (64). 
Bladder training is a behavioral intervention 
that has the purpose of progressively increasing the 
voiding intervals. It tries to restore the normal mic-
turition function by scheduling voids by the clo-
ck in order to increase the intervals between them. 
Fantl et al., in a randomized clinical trial of bladder 
training compared with a group with no interven-
tion, showed a beneficial effect of the former on the 
overactive bladder symptoms, with a 57% reduction 
of urinary incontinence episodes (65). This study’s 
weakness, however, was the small number of pa-
tients with exclusively overactive bladder. Burgio 
et al., in another randomized study of 307 women 
with urgency urinary incontinence, compared the 
use of an oral anticholinergic drug, behavioral the-
rapy, and both treatments together (66). Both the-
rapeutic groups showed improvement of urgency, 
without any significant difference. Even though, in 
the group treated with oral medication plus beha-
vioral therapy, the voiding frequency significantly 
improved (66). A systematic meta-analysis of Co-
chrane Library conducted by Rai et al. suggested 
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that patients are more likely to have favorable re-
sults when they are treated with oral anticholiner-
gics alone than when undergoing bladder training 
techniques alone (67). Although the meta-analysis 
favored the anticholinergic-treated group, it is im-
portant to stress that no individual study showed 
a statistically significant difference. In this study, 
also the treatment combination (oral anticholiner-
gic + bladder training) was superior to the bladder 
training as a monotherapy (67). 
Historically, pelvic floor physiotherapy has 
been used in the treatment of stress urinary incon-
tinence (68). However, the contraction of pelvic flo-
or muscles may have an inhibitory effect on the 
detrusor contraction. For this treatment modality, 
biofeedback and external or intracavity electrosti-
mulation may be used as additional resources. Kafri 
et al., in a randomized clinical trial, divided urgency 
urinary incontinence patients into four groups: tre-
atment with anticholinergic drugs, bladder training, 
pelvic floor physiotherapy, and a combination of 
the three treatments (69). In this study, a significant 
improvement was observed in all treatment groups, 
but those receiving the treatment combination ex-
perienced a significant voiding frequency reduction 
in more than one-year follow-up (69). 
One of the limitations of behavioral therapy 
and pelvic floor exercises is the patient’s adheren-
ce to treatment. Studies showed that up to 81% of 
patients adhered to the initial recommendations; 
12 months later, however, less than one third of 
patients were continuing the exercises. Most wo-
men tend to adhere to the exercises during super-
vised intervention, but their participation dimini-
shes over time (70). Supervised intervention can be 
carried out in group in order to reduce costs. The 
results from individual sessions and group sessions 
were similar, although patients expressed their pre-
ference to individual training (71). 
Some studies compared different modali-
ties of electrical stimulation and oral medication. 
Franzen et al. randomized a group of patients for 
treatment with tolterodine or for vaginal or anal 
electrical stimulation (72). A significant reduction 
of the voiding frequency was observed within 24 
hours in both groups. At 6 months, 73% of pa-
tients receiving electrical stimulation and 71% of 
patients treated with oral tolterodine reported less 
discomfort due to the bladder symptoms and simi-
lar improvement of the quality of life, as measured 
with the King’s Health Questionnaire (72). Ano-
ther randomized study conducted by Ozdeleli et al. 
compared transvaginal electrical stimulation with 
oral trospium by using urodynamic parameters and 
quality-of-life scales in 35 women (73). Both treat-
ments showed similar improvement of symptoms. 
The discontinuation of treatment, however, caused 
deterioration in most of the objective and subjecti-
ve overactive bladder symptoms. 
Berghmans et al. conducted a systematic 
review and meta-analysis of the electrical stimu-
lation in males that revealed the existence of only 
one study in which the real stimulation was more 
effective than the fictitious one, despite losing 
effect within up to six months (74). In all four stu-
dies included, there was no compelling evidence 
of improvement from the association of electrical 
stimulation with pelvic floor exercises when com-
pared with the exercises as monotherapy.
In 2012, Farag et al. reviewed 17 articles, 
15 of which included superficial percutaneous 
nerve stimulation of the clitoris (75). An increase 
of 11-144% of the bladder capacity was observed 
in 14 of the studies. Goldman et al., in a prospec-
tive, observational, multicentric study reported a 
reduction of at least half of the leaking episodes 
(pad test) in 76% of women (76). In the review 
of the Cochrane Library, different types of elec-
trical stimulation, such as transcutaneous, per-
cutaneous and intracavity was observed to show 
healing rates similar to the pharmacological the-
rapy. Improvement rates tend to favor the elec-
trical stimulation. However, these data were only 
significant for one clinical trial, and confirming 
them with further studies in the future is recom-
mended (67). An alternative neuromodulation 
therapy may be used for transcutaneous electro-
magnetic stimulation of sacral roots. O’Reilly et 
al., in a randomized, double-blind clinical trial 
involving 63 patients undergoing trans-sacral 
magnetic stimulation in comparison to a sham 
group could not demonstrate any significant di-
fference regarding the increase of the maximum 
voided volume in the pad test and the visual ana-
logic scale. Neither could they find a difference 
in the quality-of-life scale (77).
ibju | Overactive bladder
196
COnfLICT Of InTEREsT
 Speaker Allergan, Advisory board Astellas.
REfEREnCEs
1. Wein A. Symptom-based diagnosis of overactive bladder: an 
overview. Can Urol Assoc J. 2011;5:S135-6.
2. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans 
B, Lee J, et al. International Urogynecological Association; 
International Continence Society. An International 
Urogynecological Association (IUGA)/International 
Continence Society (ICS) joint report on the terminology 
for female pelvic floor dysfunction. Neurourol Urodyn. 
2010;29:4-20.
3. Hashim H, Abrams P. Is the bladder a reliable witness for 
predicting detrusor overactivity? J Urol. 2006;175:191-4; 
discussion 194-5.
4. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein 
AJ. How widespread are the symptoms of an overactive 
bladder and how are they managed? A population-based 
prevalence study. BJU Int. 2001;87:760-6. Erratum in: BJU 
Int 2001;88:807.
5. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn 
S, et al. Population-based survey of urinary incontinence, 
overactive bladder, and other lower urinary tract symptoms 
in five countries: results of the EPIC study. Eur Urol. 
2006;50:1306-14.
6. Tikkinen KA, Tammela TL, Rissanen AM, Valpas A, Huhtala 
H, Auvinen A. Is the prevalence of overactive bladder 
overestimated? A population-based study in Finland. PLoS 
One. 2007;2:e195.
7. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog 
AR, Corey R, et al. Prevalence and burden of overactive 
bladder in the United States. World J Urol. 2003;20:327-36.
8. Dávila HA, López V, Nieves L, Colantuono A, Guaiquirián L, 
Sánchez P, et al. Demographic distribution and prevalence 
of overactive bladder in Venezuela. Actas Urol Esp. 
2010;34:176-80.
9. Garcia Salord J, Belen R, Bevilacqua O, Cabrera R: 
Epidemiologia de la vejiga hiperactiva sobre una poblacion de 
3.692 consultas urologicas y 2.030 estudios urodinamicos. 
Rev Arg Urol. 2005;70:8-13.
10. Teloken C, Caraver F, Weber FA, Teloken PE, Moraes JF, Sogari 
PR, et al. Overactive bladder: prevalence and implications in 
Brazil. Eur Urol. 2006;49:1087-92.
11. Temml C, Heidler S, Ponholzer A, Madersbacher S. 
Prevalence of the overactive bladder syndrome by applying 
the International Continence Society definition. Eur Urol. 
2005;48:622-7.
12. Milsom I, Stewart W, Thüroff J. The prevalence of overactive 
bladder. Am J Manag Care. 2000;6:S565-73.
13. Arlandis Guzmán S, García Matres MJ, González Segura 
D, Rebollo P. [Prevalence of lower urinary tract symptoms 
in patients with overactive bladder. Patient management in 
clinical practice]. Actas Urol Esp. 2009;33:902-8.
14. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, 
Milsom I. Comorbidities and personal burden of urgency 
urinary incontinence: a systematic review. Int J Clin Pract. 
2013;67:1015-33.
15. Brocklehurst JC. Urinary incontinence in the community--
analysis of a MORI poll. BMJ. 1993;306:832-4.
16. Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, 
Mullins CD. The total economic burden of overactive bladder 
in the United States: a disease-specific approach. Am J 
Manag Care. 2009;15:S90-7.
17. Truzzi JC, Dambros M: Bexiga hiperativa: aspectos práticos. 
São Paulo, Nome da Rosa. 2009; pp. 237.
18. Gordon D, Groutz A. Evaluation of female lower urinary tract 
symptoms: overview and update. Curr Opin Obstet Gynecol. 
2001;13:521-7.
19. Fitzgerald MP, Ayuste D, Brubaker L. How do urinary diaries 
of women with na overactive bladder differ from those of 
asymptomatic controls? BJU Int. 2005;96:365-7.
20. Dmochowski RR, Sanders SW, Appell RA, Nitti VW, Davila 
GW. Bladder-health diaries: an assessment of 3-day vs 7-day 
entries. BJU Int. 2005;96:1049-54.
21. Brown JS, McNaughton KS, Wyman JF, Burgio KL, Harkaway 
R, Bergner D, et al. Measurement characteristics of a voiding 
diary for use by men and women with overactive bladder. 
Urology. 2003;61:802-9.
22. Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, 
Abrams P. The Bristol Female Lower Urinary Tract Symptoms 
questionnaire: development and psychometric testing. Br J 
Urol. 1996;77:805-12.
23. Frankel SJ, Donovan JL, Peters TI, Abrams P, Dabhoiwala NF, 
Osawa D, et al. Sexual dysfunction in men with lower urinary 
tract symptoms. J Clin Epidemiol. 1998;51:677-85.
24. Mamik MM, Rogers RG, Qualls CR, Morrow JD. The minimum 
important difference for the Pelvic Organ Prolapse-Urinary 
Incontinence Sexual Function Questionnaire. Int Urogynecol 
J. 2014;25:1321-6.
25. Oh SJ, Ku JH, Choo MS, Yun JM, Kim DY, Park WH. Health-
related quality of life and sexual function in women with 
stress urinary incontinence and overactive bladder. Int J 
Urol. 2008;15:62-7.
26. Khalili aa, Harmel mh, Forster s, benton jg. Management 
of spasticity by selective peripheral nerve block with dilute 
phenol solutions in clinical rehabilitation. Arch phys med 
rehabil. 1964;45:513-9.
27. Kelleher C, Staskin D, Cherian P. Committee 5B: Patient reported 
outcome assessment. In: Abrams P, Cardozo L, Khoury S, et al. 
5th International Consultation on Incontinence, Paris February 
2012. Available at: http://www.icud.info/incontinence.html.
ibju | Overactive bladder
197
28. Palleschi G, Pastore AL, Stocchi F, Bova G, Inghilleri M, 
Sigala S, et al. Correlation between the Overactive Bladder 
questionnaire (OAB-q) and urodynamic data of Parkinson 
disease patients affected by neurogenic detrusor overactivity 
during antimuscarinic treatment. Clin Neuropharmacol. 
2006;29:220-9.
29. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo 
L, Chapple C, et al. Fourth International Consultation 
on Incontinence. Fourth International Consultation on 
Incontinence Recommendations of the International Scientific 
Committee: Evaluation and treatment of urinary incontinence, 
pelvic organ prolapse, and fecal incontinence. Neurourol 
Urodyn. 2010;29:213-40.
30. Rovner ES, Gomes CM, Trigo-Rocha FE, Arap S, Wein AJ. 
Evaluation and treatment of the overactive bladder. Rev Hosp 
Clin Fac Med Sao Paulo. 2002;57:39-48.
31. Fantl JA, Newman DK, Colling J: Urinary incontinence in 
adults: Acute and chronic management. Rockville, MD: U.S. 
Department of Health and Human Services, Public Health 
Service, Agency for Health Care Policy and Research, 1996.
32. Caruso DJ, Kanagarajah P, Cohen BL, Ayyathurai R, Gomez 
C, Gousse AE. What is the predictive value of urodynamics 
to reproduce clinical findings of urinary frequency, urge 
urinary incontinence, and/or stress urinary incontinence? 
Int Urogynecol J. 2010;21:1205-9.
33. Digesu GA, Salvatore S, Fernando R, Khullar V. Mixed 
urinary symptoms: what are the urodynamic findings? 
Neurourol Urodyn. 2008;27:372-5.
34. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe 
B; GENULF. The neurogenic bladder in multiple sclerosis: 
review of the literature and proposal of management 
guidelines. Mult Scler. 2007;13:915-28.
35. Botelho MG, Chan AW, Yiu EY, Tse ET. Longevity of two-unit 
cantilevered resin-bonded fixed partial dentures. Am J Dent. 
2002;15:295-9.
36. Ghezzi A, Carone R, Del Popolo G, Amato MP, Bertolotto A, 
Comola M, et al. Multiple Sclerosis Study Group, Italian Society 
of Neurology. Recommendations for the management of urinary 
disorders in multiple sclerosis: a consensus of the Italian 
Multiple Sclerosis Study Group. Neurol Sci. 2011;32:1223-31.
37. Bosch JL, Cardozo L, Hashim H, Hilton P, Oelke M, Robinson 
D. Constructing trials to show whether urodynamic studies are 
necessary in lower urinary tract dysfunction. Neurourol Urodyn. 
2011;30:735-40.
38. Scarpero H. Urodynamics in the evaluation of female LUTS: 
when are they helpful and how do we use them? Urol Clin North 
Am. 2014;41:429-38, viii-ix.
39. Dobbs RW, Hugar LA, Revenig LM, Al-Qassab S, Petros JA, 
Ritenour CW, et al. Incidence and clinical characteristics of 
lower urinary tract symptoms as a presenting symptom for 
patients with newly diagnosed bladder cancer. Int Braz J Urol. 
2014;40:198-203.
40. Antunes-Lopes T, Cruz CD, Cruz F, Sievert KD. Biomarkers in 
lower urinary tract symptoms/overactive bladder: a critical 
overview. Curr Opin Urol. 2014;24:352-7.
41. Seki S, Sasaki K, Fraser MO, Igawa Y, Nishizawa O, Chancellor 
MB, et al. Immunoneutralization of nerve growth factor in 
lumbosacral spinal cord reduces bladder hyperreflexia in spinal 
cord injured rats. J Urol. 2002;168:2269-74.
42. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor 
levels are elevated in patients with detrusor overactivity and 
decreased in responders to detrusor botulinum toxin-A injection. 
Eur Urol. 2009;56:700-6.
43. Kuo HC, Liu HT, Chancellor MB. Can urinary nerve growth 
factor be a biomarker for overactive bladder? Rev Urol. 
2010;12:e69-77.
44. Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK. 
Changes of urinary nerve growth factor and prostaglandins 
in male patients with overactive bladder symptom. Int J Urol. 
2005;12:875-80.
45. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve 
growth factor but not prostaglandin E2 increases in patients 
with interstitial cystitis/bladder pain syndrome and detrusor 
overactivity. BJU Int. 2010;106:1681-5.
46. Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor levels in 
overactive bladder syndrome and lower urinary tract disorders. 
J Formos Med Assoc. 2010;109:862-78.
47. Qu HC, Yan S, Zhang XL, Zhu XW, Liu YL, Wang P. Urinary nerve 
growth fator levels could be a biomarker for overactive bladder 
symptom: a meta-analysis. Genet Mol Res. 2014;13:8609-19.
48. Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, 
Vodovotz Y, et al. Urine cytokines suggest an inflammatory 
response in the overactive bladder: a pilot study. Int Urol 
Nephrol. 2010;42:629-35.
49. Ghoniem G, Faruqui N, Elmissiry M, Mahdy A, Abdelwahab 
H, Oommen M, et al. Differential profile analysis of 
urinary cytokines in patients with overactive bladder. Int 
Urogynecol J. 2011;22:953-61. Erratum in: Int Urogynecol 
J. 2011;22:1069.
50. Chung SD, Liu HT, Lin H, Kuo HC. Elevation of serum 
c-reactive protein in patients with OAB and IC/BPS implies 
chronic inflammation in the urinary bladder. Neurourol 
Urodyn. 2011;30:417-20.
51. Hsiao SM, Lin HH, Kuo HC. The role of serum C-reactive 
protein in women with lower urinary tract symptoms. Int 
Urogynecol J. 2012;23:935-40.
52. Silva-Ramos M, Silva I, Oliveira O, Ferreira S, Reis MJ, 
Oliveira JC, et al. Urinary ATP may be a dynamic biomarker 
of detrusor overactivity in women with overactive bladder 
syndrome. PLoS One. 2013;8:e64696.
53. Sun Y, Keay S, De Deyne PG, Chai TC. Augmented stretch 
activated adenosine triphosphate release from bladder 
uroepithelial cells in patients with interstitial cystitis. J Urol. 
2001;166:1951-6.
ibju | Overactive bladder
198
54. Cheng Y, Mansfield KJ, Allen W, Millard RJ, Burcher E, 
Moore KH. Correlation between cystometric volumes, ATP 
release, and pH in women with overactive bladder versus 
controls. Neurourol Urodyn. 2013;32:969-73.
55. Nishijima S, Sugaya K, Kadekawa K, Naka H, Miyazato M. 
Comparison of the effect of anti-muscarinic agents on 
bladder activity, urinary ATP level, and autonomic nervous 
system in rats. Biomed Res. 2009;30:107-12.
56. Creighton SM, Stanton SL. Caffeine: does it affect your 
bladder? Br J Urol. 1990;66:613-4.
57. Arya LA, Myers DL, Jackson ND. Dietary caffeine intake 
and the risk for detrusor instability: a case-control study. 
Obstet Gynecol. 2000;96:85-9.
58. Holroyd-Leduc JM, Straus SE. Management of urinary 
incontinence in women: scientific review. JAMA. 
2004;291:986-95.
59. Tomlinson BU, Dougherty MC, Pendergast JF, Boyington 
AR, Coffman MA, Pickens SM. Dietary caffeine, fluid 
intake and urinary incontinence in older rural women. Int 
Urogynecol J Pelvic Floor Dysfunct. 1999;10:22-8.
60. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction 
education to improve urinary symptoms. Br J Nurs. 
2002;11:560-5.
61. Wells MJ, Jamieson K, Markham TC, Green SM, Fader MJ. 
The effect of caffeinated versus decaffeinated drinks on 
overactive bladder: a double-blind, randomized, crossover 
study. J Wound Ostomy Continence Nurs. 2014;41:371-8.
62. Swithinbank L, Hashim H, Abrams P. The effect of 
fluid intake on urinary symptoms in women. J Urol. 
2005;174:187-9.
63. Hashim H, Abrams P. How should patients with an 
overactive bladder manipulate their fluid intake? BJU 
Int. 2008;102:62-6.
64. Ouslander JG, Schnelle JF. Incontinence in the nursing 
home. Ann Intern Med. 1995;122:438-49.
65. Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, 
Taylor JR, et al. Efficacy of bladder training in older women 
with urinary incontinence. JAMA. 1991;265:609-13.
66. Burgio KL, Kraus SR, Borello-France D, Chai TC, Kenton K, 
Goode PS, et al. Urinary Incontinence Treatment Network. 
The effects of drug and behavior therapy on urgency and 
voiding frequency. Int Urogynecol J. 2010;21:711-9.
67. Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic 
drugs versus non-drug active therapies for non-neurogenic 
overactive bladder syndrome in adults. Cochrane Database 
Syst Rev. 2012;12:CD003193.
68. KEGEL AH. Progressive resistance exercise in the functional 
restoration of the perineal muscles. Am J Obstet Gynecol. 
1948;56:238-48.
69. Kafri R, Deutscher D, Shames J, Golombp J, Melzer I. 
Randomized trial of a comparison of rehabilitation or drug 
therapy for urgency urinary incontinence: 1-year follow-up. 
Int Urogynecol J. 2013;24:1181-9.
70. Borello-France D, Burgio KL, Goode PS, Markland AD, 
Kenton K, Balasubramanyam A, et al. Urinary Incontinence 
Treatment Network. Adherence to behavioral interventions 
for urge incontinence when combined with drug therapy: 
adherence rates, barriers, and predictors. Phys Ther. 
2010;90:1493-505.
71. Lamb SE, Pepper J, Lall R, Jørstad-Stein EC, Clark MD, Hill 
L, et al. Group treatments for sensitive health care problems: 
a randomised controlled trial of group versus individual 
physiotherapy sessions for female urinary incontinence. 
BMC Womens Health. 2009;9:26.
72. Franzén K, Johansson JE, Lauridsen I, Canelid J, Heiwall B, 
Nilsson K. Electrical stimulation compared with tolterodine 
for treatment of urge/urge incontinence amongst women--a 
randomized controlled trial. Int Urogynecol J. 2010;21:1517-24.
73. Ozdedeli S, Karapolat H, Akkoc Y. Comparison of intravaginal 
electrical stimulation and trospium hydrochloride in women 
with overactive bladder syndrome: a randomized controlled 
study. Clin Rehabil. 2010;24:342-51.
74. Berghmans B, Hendriks E, Bernards A, de Bie R, Omar MI. 
Electrical stimulation with non-implanted electrodes for 
urinary incontinence in men. Cochrane Database Syst Rev. 
2013;6:CD001202.
75. Farag FF, Martens FM, Rijkhoff NJ, Heesakkers JP. 
Dorsal genital nerve stimulation in patients with detrusor 
overactivity: a systematic review. Curr Urol Rep. 
2012;13:385-8.
76. Goldman HB, Amundsen CL, Mangel J, Grill J, Bennett M, 
Gustafson KJ, et al. Dorsal genital nerve stimulation for 
the treatment of overactive bladder symptoms. Neurourol 
Urodyn. 2008;27:499-503.
77. O’Reilly BA, Fynes M, Achtari C, Hiscock R, Thomas E, 
Murray C, et al. A prospective randomised double-blind 
controlled trial evaluating the effect of trans-sacral magnetic 
stimulation in women with overactive bladder. Int Urogynecol 
J Pelvic Floor Dysfunct. 2008;19:497-502.
_______________________
Correspondence address:
Jose Carlos Truzzi, MD
Escola Paulista de Medicina - EPM,
Universidade Federal de São Paulo,
Rua Dr. Oscar Monteiro de Barros, 617 / 141
São Paulo, SP, 05641-010, Brasil
E-mail: jctruzzi@hotmail.com
